Distinguished Speakers


Ambar Ahmed, Senior Scientific Manager, Oncology Translational Sciences, AstraZeneca

John L. Allinson, FIBMS, Vice President, Biomarker Services, Biologics Development Services, Tampa Bay


Robert A. Anders, MD, PhD, Associate Professor, Pathology; Co-Director, Tumor Microenvironment Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University

Brittany Bahamon, Scientist I, Translation & Biomarker Research, Takeda Pharmaceuticals, Inc.


Roy D. Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories


Robert A. Beckman, MD, Professor, Oncology, Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center


Michael J. Benecky, PhD, Senior Director, Global Regulatory Affairs, Precision and Digital Medicine, R&D Chief Regulatory Office, GlaxoSmithKline


Peter Bergethon, MD, Vice President, Quantitative Medicine and Clinical Technologies, Biogen


Erhan Bilal, PhD, Researcher, IBM T.J. Watson Research/Computational Biology Center


Marijo Bilusic, MD, PhD, Associate Research Physician, National Cancer Institute, National Institutes of Health


Darrell R. Borger, PhD, Scientific Director, Immuno-Profiling Laboratory; Director, Translational Research/Biomarker Laboratory, Massachusetts General Hospital Cancer Center

Tullia Bruno, PhD, Research Assistant Professor, Immunology, University of Pittsburgh


Michael E. (Ted) Burczynski, PhD, PPM Expert, Director, Personalized & Predictive Medicine, Analytics & Big Data, Teva Pharmaceuticals

Amanda J. Centi, PhD, Research Program Manager, Connect Health Innovation, Partners HealthCare


Yu-Feng Yvonne Chan, MD, PhD, Associate Professor, Genetics and Genomics Sciences & Emergency Medicine; Director, Center for Digital Health, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai


Pratip Chattopadhyay, PhD, Associate Professor, Pathology; Director, Precision Immunology Incubator, Isaac and Laura Perlmutter Cancer Center, New York University Langone Medical Center

Carolyn Compton, MD, PhD, Professor, Life Science, Arizona State University; CMO, ASU Complex Adaptive Systems Institute; CMO, National Biomarker Development Alliance


Mark E. Curran, PhD, Vice President and Head of Companion Diagnostics, Janssen Immunology


Viswanath Devanarayan, PhD, Global Head of Statistics & Data Sciences, Charles River Laboratories


Kenneth Emancipator, MD, Executive Medical Director and Head of Companion Diagnostics, Merck & Co.


Steven Fling, PhD, Senior Staff Scientist, Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Research Center; Director, Cancer Immunotherapy Trials Network Immune Monitoring Laboratory


Shirin Khambata Ford, PhD, Global Head, Biomarkers and Diagnostics, Executive Director, Oncology Global Medical Affairs, Merck


Bernard A. Fox, PhD, Harder Family Chair for Cancer Research, Member and Chief, Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Portland Medical Center; CEO, UbiVac


Mark Frasier, PhD, Senior Vice President, Research Programs, The Michael J. Fox Foundation for Parkinson’s Research


Tim Fugmann, PhD, Head, Precision Medicine, Philochem AG


Jianjun Gao, MD, PhD, Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center


Arnold B. Gelb, MD, Senior Director, Clinical Development, Ziopharm Oncology


Marios Giannakis, MD, PhD, Medical Oncologist & Clinical Investigator, Dana-Farber Gastrointestinal Cancer Treatment Center; Researcher, Broad Institute of MIT and Harvard


Sacha Gnjatic, PhD, Associate Professor, Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai


Christian Gossens, PhD, MBA, Global Head, Early Development Workflows, pRED Informatics, Roche Pharmaceutical Research and Early Development


Daniel Grant, PhD, Director, Early Development Lead, Novartis


George A. Green, IV, PhD, Head, Pharmacodiagnostics, Bristol-Myers Squibb


Abdel B. Halim, PharmD, PhD, DABCC, FAACC, Vice President, Translational Medicine, Biomarkers & Diagnostics, Celldex Therapeutics


Gerald Hall, PhD, Principal Research Scientist, Experimental and Translational Immuno-Oncology: Biomarkers, Eli Lilly


Samir Hanash, MD, PhD, Director, McCombs Institute for Cancer Early Detection and Treatment, MD Anderson Cancer Center


Brent A. Hanks, MD, PhD, Assistant Professor, Cancer Immunology/Immunotherapy, Duke Cancer Institute


Christopher M. Hartshorn, PhD, Program Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health


Elena Izmailova, PhD, Senior Director, Novel Data Streams and Devices, Data Science Institute, Takeda Pharmaceuticals International, Inc.


Vladimir Jankovic, MD, Director, Precision Medicine, Early Clinical Development & Experimental Sciences, Regeneron


Filip Janku, MD, PhD, Associate Professor, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center


Sarah Javaid, PhD, Associate Principal Scientist, Merck


John Milburn Jessup, MD, Scientific Director, Precision Cancer Care Program, Inova Schar Cancer Institute; Professor, Systems Biology, Krasnow Institute of Advanced Study, George Mason University

Shidong Jia, PhD, Founder & CEO, Predicine


Bruce E. Johnson, MD, Professor of Medicine, Harvard Medical School


Karin Jooss, PhD, CSO, Gritstone Oncology


Pawel Kalinski, MD, PhD, Professor, Oncology, Vice-Chair, Translational Research, Roswell Park Cancer Institute


Maria Karasarides, PhD, Executive Director, Immuno-Oncology, Regeneron Pharmaceuticals


Daniel Karlin, MD, Head, Experimental Medicine, Informatics & Regulatory Strategy, Pfizer


Mark Lackner, PhD, Director and Principal Scientist, Genentech


Marc Ladanyi, MD, William J. Ruane Chair in Molecular Oncology, Molecular Diagnostics Service and Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center


Rebecca Leary, PhD, Lab Head, Next Generation Diagnostics, Novartis Institutes for BioMedical Research


Joel Lefferts, PhD, Assistant Professor, Pathology, Assistant Director, Clinical Genomics and Advanced Technology (CGAT), Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center

Mingjie Liu, PhD, Clinical Biomarker Lead, Translational Science, Oncology Business Group, Eisai


Andrey Loboda, PhD, Director, Genetics and Pharmacogenomics, Merck


Christina Lockwood, PhD, Associate Professor, Director, Genetics and Solid Tumors Laboratory, University of Washington

Rajyalakshmi (Raja) Luthra, PhD, Director, Molecular Diagnostics Laboratory; Director, Molecular Genetics Pathology Fellowship Program; Professor, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center

Kathleen M. Mahoney, MD, PhD, Clinical Instructor, Beth Israel Deaconess Medical Center; Research Fellow, Dana-Farber Cancer Institute


Christopher Major, PhD, Scientific Director, Diagnostic Development, Janssen


Rajarsi Mandal, MD, Head and Neck Surgical Oncology Fellow, Memorial Sloan Kettering Cancer Center


Sanjeev Mariathasan, PhD, Senior Scientist, Oncology Biomarker Department, Genentech


James R. Mault, MD, FACS, Senior Vice President and CMO, Qualcomm Life


Jennifer J.D. Morrissette, PhD, Scientific Director, Clinical Cancer Cytogenetics, Clinical Director, Center for Personalized Diagnostics, University of Pennsylvania


Carol Anne Ogden, PhD, Senior Manager and ADCETRIS Biomarker Lead, Diagnostics and Biomarkers, Seattle Genetics, Inc.


Shuji Ogino, MD, PhD, Professor (Pathology & Epidemiology), Brigham & Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health; Associate Member, Broad Institute of MIT and Harvard

Elena Orlando, PhD, Bioinformatics Investigator, Novartis Institutes for BioMedical Research

Adam C. Palmer, PhD, Postdoctoral Fellow, Harvard Program in Therapeutic Science, Harvard Medical School


Tushar Parlikar, PhD, Product Manager, Verily Life Sciences


Bakul Patel, Associate Director, Digital Health, FDA

Kinjal R. Patel, Senior Study Manager, Clinical Sciences, Bayer US


Tracy Petrie, PhD, MoleMapper Product Manager, Oregon Health & Science University


Robert Pierce, MD, Scientific Director, Immunopathology Core, Fred Hutchinson Cancer Research Center


Katerina Politi, PhD, Associate Professor, Pathology, Yale School of Medicine


George Poste, DVM, PhD, Chief Scientist, Complex Adaptive Systems, Regents’ Professor and Del E. Webb Chair in Health Innovation, Arizona State University


Osama Rahma, MD, Assistant Professor, Medicine, Dana-Farber Cancer Institute, Harvard Medical School


Fred Ramsdell, PhD, Vice President, Research, Parker Institute for Cancer Immunotherapy


Susanne K. Rhoades, PhD, Director, Diagnostics Development, Tailored Therapeutics, Eli Lilly and Company


David L. Rimm, MD, PhD, Professor, Pathology, Yale University

Edwin Rock, MD, PhD, Vice President, Clinical Research, MacroGenics, Inc.


David B. Roth, MD, PhD, Simon Flexner Professor and Chair, Department of Pathology and Laboratory Medicine Director, Penn Center for Precision Medicine


Kurt Schalper, MD, PhD, Assistant Professor, Pathology and Medicine (Medical Oncology), Yale School of Medicine


Emmett Schmidt, MD, PhD, Scientific Associate Vice President, Merck Research Labs


Cecilia Schott, PharmD, MBA, Former Vice President, Precision Medicine, AstraZeneca Oncology Business Unit


Peter M. Shaw, PhD, Head, Clinical Pharmacogenetics, Merck


Daniel Stetson, PhD, Associate Principal Scientist, AstraZeneca


Ryan J. Sullivan, MD, Assistant Professor, Hematology & Oncology, Massachusetts General Hospital; Assistant Professor, Medicine, Harvard Medical School

Bakhos A. Tannous, PhD, Associate Professor, Neurology, Harvard Medical School; Director, Experimental Therapeutics and Molecular Imaging Lab; Director, Interdepartmental Neuroscience Center; Director, MGH Viral Vector Development Facility, Massachusetts General Hospital

Iman Tavassoly, MD, PhD, Research Fellow, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai

Raymond Tesi, MD, President and CEO, Acting CMO, INmune Bio


Elizabeth Thompson, MD, PhD, Assistant Professor, Pathology and Oncology, The Johns Hopkins University School of Medicine


Gregory Tsongalis, PhD, Professor, Pathology & Laboratory Medicine, Dartmouth College


Gabriel Vargas, MD, PhD, Executive Medical Director, Digital Health & Neuroscience Therapeutic Area Head, Early Development, Amgen


Dan E. Webster, PhD, Principal Scientist of Digital Health, Sage Bionetworks


Glen J. Weiss, MD, MBA, Director, Phase I Clinical Research, Beth Israel Deaconess Medical Center, Boston


Theresa L. Whiteside, PhD, Professor, Pathology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute


Timothy Yap, MD, PhD, Associate Professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center


Jianda Yuan, MD, PhD, Senior Director, Translational Oncology, Early Clinical Oncology Development, Merck Research Labs